STE Prince Pharma Sarl Pharmaceutical Import Profile — Congo Dr (DGFT 2022–2026)

Name: STE Prince Pharma Sarl Pharmaceutical Import Records from India — 8 Products, $6.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

STE Prince Pharma Sarl — Pharmaceutical Importer Profile (2026) | 8 Products, $6.3M Trade | TransData Nexus

STE Prince Pharma Sarl

Pharmaceutical Importer · Congo Dr · Antibiotics Focus · $6.3M Total Trade · DGFT Verified

STE Prince Pharma Sarl is a pharmaceutical importer based in Congo Dr with a total trade value of $6.3M across 8 products in 5 therapeutic categories. Based on 422 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. STE Prince Pharma Sarl sources from 32 verified Indian suppliers, with Prashi Pharma Private Limited accounting for 56.1% of imports.

STE Prince Pharma Sarl — Import Portfolio & Supplier Network

STE Prince Pharma Sarl import network — 8 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to STE Prince Pharma Sarl?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Prashi Pharma Private Limited	$16.4M	1,417	56.1%
Vidacare Medica Private Limited	$3.3M	281	11.2%
Lykis Limited	$1.3M	216	4.3%

What Formulations Does STE Prince Pharma Sarl Import?

Formulation	Value	Ships
Tetracycline capsule BP 250 MG Each CAPS	$564.0K	19
Cypro-500 tablets Each film coated	$538.0K	22
Metro - 250 tablets Each film coated	$514.7K	25
Volpa tablets Each uncoated tablets	$398.1K	26
Ibutec forte capsules Each capsules	$331.5K	12
Griseofulvin tablets b.p. 500 MG Each	$316.4K	10
Tetracycline capsule BP 250 MG Each capsule contains: tetracycline hcl BP 250 MG	$314.4K	18
Paracetamol tablets b p 500 MG Each uncoated tablets contains paracetamol b p 500 MG	$267.4K	7
Diclofenac tablets 50MG Each film coated tablets contains : diclofenac sodiumb.p. 50 MG	$253.4K	12
Ibutec capsules Each capsules	$252.8K	10
Tetracycline casule BP 250 MG Each	$250.9K	9
Lincomycin capsule BP 500MG Each	$243.2K	9
Metro - 250 tablets Each film coated tablets contains :metronidazole b.p. 250 MG	$237.6K	14
Metro - 250 tablets Each film coated tablets contains : metronidazole b.p. 250 MG	$223.8K	15
Ibuprofen tablets BP 400MG Each film coated tablet contains : ibuprofen BP 400 MG	$218.7K	17

STE Prince Pharma Sarl imports 1,395 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 8 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Tetracycline	Antibiotics	$1.8M	72	10.8%	2
2	Caffeine	Respiratory & OTC	$1.2M	91	1.1%	11
3	Metronidazole	Advanced Antibiotics	$1.0M	100	0.5%	18
4	Griseofulvin	Advanced Antifungals	$687.3K	31	1.9%	4
5	Erythromycin	Antibiotics	$634.3K	30	0.8%	12
6	Mebendazole	Antimalarial & Antiparasitic	$452.0K	42	3.3%	4
7	Trimethoprim	Advanced Antibiotics	$319.3K	38	1.2%	15
8	Levamisole	Antimalarial & Antiparasitic	$189.5K	18	7.1%	4

STE Prince Pharma Sarl imports 8 pharmaceutical products across 5 categories into Congo Dr totaling $6.3M.

STE Prince Pharma Sarl — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

STE Prince Pharma Sarl is a prominent pharmaceutical importer and distributor based in Kinshasa, the capital of the Democratic Republic of Congo (DRC). Established in 2004, the company specializes in sourcing and distributing a diverse range of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Their product portfolio spans multiple therapeutic categories, reflecting a commitment to addressing various healthcare needs within the DRC. STE Prince Pharma Sarl plays a pivotal role in the DRC's pharmaceutical supply chain, ensuring the availability of essential medicines across the country.

2Distribution Network

STE Prince Pharma Sarl operates a comprehensive distribution network throughout the DRC, encompassing both urban centers and remote regions. Their logistics capabilities include a modern, ISO 9001:2015-certified warehouse equipped with advanced inventory management systems. This infrastructure ensures efficient storage, handling, and distribution of pharmaceutical products, maintaining the integrity and quality of medicines during transit. The company's strategic distribution approach facilitates widespread access to healthcare products, contributing to improved health outcomes across the nation.

3Industry Role

In the DRC's pharmaceutical supply chain, STE Prince Pharma Sarl functions primarily as a wholesaler and distributor. By importing finished pharmaceutical formulations from international suppliers, particularly from India, the company bridges the gap between global manufacturers and local healthcare providers. This role is crucial in ensuring a steady supply of essential medicines, thereby supporting the healthcare infrastructure and meeting the therapeutic needs of the Congolese population.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — STE Prince Pharma Sarl

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

STE Prince Pharma Sarl's sourcing strategy exhibits a high degree of concentration, with a significant portion of imports originating from a select group of Indian suppliers. For instance, PRASHI PHARMA PRIVATE LIMITED accounts for 56.1% of the total import value, while VIDACARE MEDICA PRIVATE LIMITED contributes 11.2%. This concentrated sourcing approach may offer benefits such as streamlined logistics and potentially favorable pricing. However, it also introduces risks related to supply chain disruptions, as dependency on a limited number of suppliers can lead to vulnerabilities if any of these suppliers face operational challenges. The stability of these supplier relationships is critical to maintaining a consistent supply of pharmaceutical products.

2Supply Chain Resilience

The resilience of STE Prince Pharma Sarl's supply chain is closely tied to the stability and reliability of its Indian suppliers. While the company imports a diverse range of formulations, the heavy reliance on a few suppliers suggests limited diversification in sourcing. This lack of diversification could pose challenges in the event of disruptions such as production delays, regulatory changes, or geopolitical issues affecting supplier countries. To enhance supply chain resilience, it would be prudent for STE Prince Pharma Sarl to consider expanding its supplier base and establishing relationships with additional manufacturers. Ensuring that suppliers adhere to recognized Good Manufacturing Practice (GMP) standards is also essential to maintain product quality and regulatory compliance.

Importing Pharmaceuticals into Congo Dr — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Congo Dr

1Regulatory Authority & Framework

The Congolese Pharmaceutical Regulatory Authority (ACOREP) is responsible for overseeing the importation and marketing of pharmaceutical products in the DRC. ACOREP ensures that imported medicines meet the country's health and safety standards, safeguarding public health. Key legislation governing pharmaceutical imports includes the Pharmaceutical Law, which outlines the requirements for import licenses, product registration, and quality control measures. The marketing authorization pathway for Indian generics involves obtaining approval from ACOREP, which assesses the safety, efficacy, and quality of the products before granting authorization for sale in the DRC.

2Import Licensing & GMP

Importers in the DRC must secure an import license from an authorized commercial bank, a process that includes a pre-shipment inspection by Bureau Veritas for shipments valued over a specified amount. While Good Manufacturing Practice (GMP) certification is officially required, enforcement can be inconsistent. A Certificate of Pharmaceutical Product (CPP) is a critical document in the import process. For quality control, initial screening is conducted locally using methods like the GPHF Minilab, with more comprehensive analysis performed at WHO-prequalified laboratories abroad. The entire process, from clinical trial application to market entry, is managed by ACOREP, which aims to provide a decision on clinical trial applications within 30 days of submission, following ethics committee approval.

STE Prince Pharma Sarl — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

STE Prince Pharma Sarl's product category focus on antibiotics, advanced antibiotics, and respiratory & OTC medications aligns with the prevalent health challenges in the DRC, such as infectious diseases and respiratory conditions. The substantial import values in these categories indicate a strategic emphasis on addressing critical therapeutic needs. Market demand for these products is driven by factors like disease prevalence, healthcare infrastructure, and patient access to essential medicines. By concentrating on these therapeutic areas, STE Prince Pharma Sarl aims to provide effective solutions to pressing health issues within the country.

2Sourcing Profile

STE Prince Pharma Sarl's sourcing strategy is centered on importing generic pharmaceutical formulations from India, a country known for its robust pharmaceutical manufacturing sector. The company's preference for finished formulations over raw Active Pharmaceutical Ingredients (APIs) suggests a focus on ready-to-use products that meet the immediate needs of the Congolese market. India's adherence to recognized GMP standards and the availability of a wide range of generic medicines make it a strategic sourcing partner for STE Prince Pharma Sarl.

3Market Positioning

Seller's Guide — How to Become a Supplier to STE Prince Pharma Sarl

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with STE Prince Pharma Sarl, especially if they can offer high-quality products that meet the therapeutic needs of the DRC market. Gaps in STE Prince Pharma Sarl's current sourcing may include specific formulations or therapeutic areas not fully addressed by existing suppliers. By identifying these gaps and offering tailored solutions, new suppliers can establish valuable partnerships and expand their market presence in the DRC.

2Requirements & Qualifications

Indian exporters seeking to supply STE Prince Pharma Sarl and the DRC market must ensure that their products comply with ACOREP's regulatory requirements, including obtaining necessary import licenses and marketing authorizations. Products should be manufactured in facilities adhering to recognized GMP standards, and exporters must provide Certificates of Pharmaceutical Product (CPP) to facilitate the import process. Additionally, compliance with labeling regulations, including the use of French on all documentation and labeling, is essential.

3How to Approach

Frequently Asked Questions — STE Prince Pharma Sarl

What products does STE Prince Pharma Sarl import from India?

STE Prince Pharma Sarl imports 8 pharmaceutical products across 5 categories. Top imports: Tetracycline ($1.8M), Caffeine ($1.2M), Metronidazole ($1.0M), Griseofulvin ($687.3K), Erythromycin ($634.3K).

Who supplies pharmaceuticals to STE Prince Pharma Sarl from India?

STE Prince Pharma Sarl sources from 32 verified Indian suppliers. The primary supplier is Prashi Pharma Private Limited (56.1% of imports, $16.4M).

What is STE Prince Pharma Sarl's total pharmaceutical import value?

STE Prince Pharma Sarl's total pharmaceutical import value from India is $6.3M, based on 422 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does STE Prince Pharma Sarl focus on?

STE Prince Pharma Sarl imports across 5 categories. The largest: Antibiotics (38.7%), Advanced Antibiotics (21.1%), Respiratory & OTC (19.3%).

Get Full STE Prince Pharma Sarl Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.